Correction: Anti-tumor effects of ONC201 in combination with VEGF-inhibitors significantly impacts colorectal cancer growth and survival in vivo through complementary non-overlapping mechanisms

Abstract

Correction: J Exp Clin Cancer Res 37, 11 (2018)

https://doi.org/10.1186/s13046-018-0671-0

Following publication of the original article [1], the authors have been alerted to an error in Fig. 3A that shows a duplication of a histological image in two panels in the figure. This image duplication error in Fig. 3A was missed by all the authors and reviewers of the paper.

Incorrect Fig. 3

Fig. 3

ONC201 does not impact VEGF expression in xenografts or HUVEC sprouting. a VEGF-A expression as detected by immunohistochemistry in HT29 and HCT116 CRC xenografts. b HUVEC representative images of sprouting from HUVECs grown on Matrigel. c Quantitation of HUVEC sprouting and branching after 12 h of drug treatment. In vivo: n = 5 ONC201 treatment dose was 50 mg/kg weekly. HUVECS N = 4, ONC201 treatment dose 5 μM, bevacizumab dose 5 mg/ml

Full size image

Correct Fig. 3

Fig. 3

ONC201 does not impact VEGF expression in xenografts or HUVEC sprouting. a VEGF-A expression as detected by immunohistochemistry in HT29 and HCT116 CRC xenografts. b HUVEC representative images of sprouting from HUVECs grown on Matrigel. c Quantitation of HUVEC sprouting and branching after 12 h of drug treatment. In vivo: n = 5 ONC201 treatment dose was 50 mg/kg weekly. HUVECS N = 4, ONC201 treatment dose 5 μM, bevacizumab dose 5 mg/ml

Full size image

1. Wagner J, Kline C, Zhou L, et al. Anti-tumor effects of ONC201 in combination with VEGF-inhibitors significantly impacts colorectal cancer growth and survival in vivo through complementary non-overlapping mechanisms. J Exp Clin Cancer Res. 2018;37:11. https://doi.org/10.1186/s13046-018-0671-0.

   Article CAS PubMed PubMed Central Google Scholar

Download references

Authors and Affiliations

1. Laboratory of Translational Oncology and Experimental Cancer Therapeutics, Molecular Therapeutics Program and Department of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA

   Jessica Wagner, C. Leah Kline, Lanlan Zhou & Wafik S. El-Deiry

2. NexusPharma, Inc., Philadelphia, PA, USA

   Vladimir Khazak

Authors

1. Jessica WagnerView author publications

   You can also search for this author in PubMed Google Scholar

2. C. Leah KlineView author publications

   You can also search for this author in PubMed Google Scholar

3. Lanlan ZhouView author publications

   You can also search for this author in PubMed Google Scholar

4. Vladimir KhazakView author publications

   You can also search for this author in PubMed Google Scholar

5. Wafik S. El-DeiryView author publications

   You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Wafik S. El-Deiry.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

Cite this article

Wagner, J., Kline, C.L., Zhou, L. et al. Correction: Anti-tumor effects of ONC201 in combination with VEGF-inhibitors significantly impacts colorectal cancer growth and survival in vivo through complementary non-overlapping mechanisms. J Exp Clin Cancer Res 43, 257 (2024). https://doi.org/10.1186/s13046-024-03185-7

Download citation

• Published: 11 September 2024

• DOI: https://doi.org/10.1186/s13046-024-03185-7

Share this article

Anyone you share the following link with will be able to read this content:

Get shareable link

Sorry, a shareable link is not currently available for this article.

Copy to clipboard

Provided by the Springer Nature SharedIt content-sharing initiative